Related Experiment Video

Updated: Mar 18, 2026

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors
08:45

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors

Published on: July 17, 2020

6.7K

Recent advances in the development of protein tyrosine phosphatase 1B inhibitors for Type 2 diabetes

Shan Qian1, Man Zhang1, Yanying He1

  • 1School of Food & Biotechnology, Xihua University, Chengdu 610039, PR China.

Future Medicinal Chemistry
|July 1, 2016
PubMed

Insights

Type 2 diabetes (T2D) involves insulin resistance, where Protein Tyrosine Phosphatase 1B (PTP1B) plays a key role. Recent research focuses on PTP1B inhibitors as a therapeutic strategy for T2D.

Area of Science:

  • Biochemistry
  • Metabolic Disorders
  • Pharmacology

Background:

  • Diabetes mellitus is a global health concern, with Type 2 diabetes (T2D) characterized by insulin resistance.
  • Protein Tyrosine Phosphatase 1B (PTP1B) is a critical negative regulator of insulin signaling pathways.
  • Dysregulation of PTP1B contributes significantly to the pathophysiology of T2D.

Purpose of the Study:

  • To review recent research (2012-2015) on the role of PTP1B in T2D.
  • To highlight novel PTP1B inhibitors as potential therapeutic agents for T2D.
  • To discuss the chemical structures and mechanisms of action of these inhibitors.

Main Methods:

  • Literature review of scientific publications from 2012-2015.
  • Analysis of research on PTP1B's role in insulin signal transduction.
  • Examination of novel PTP1B inhibitors, their structures, and modes of action.

Main Results:

  • PTP1B is confirmed as a key player in T2D pathogenesis through its modulation of insulin signaling.
  • Several novel PTP1B inhibitors have been identified and characterized.
  • These inhibitors show promise in preclinical studies for managing T2D.

Conclusions:

  • PTP1B remains a significant therapeutic target for Type 2 diabetes.
  • Ongoing research into PTP1B inhibitors offers potential for improved T2D management.
  • Understanding PTP1B's role in signal transduction is crucial for developing effective treatments.
Keywords:
Type 2 diabetesinsulin resistanceprotein tyrosine phosphatase 1B

More Related Videos

Author Spotlight: Developing Tools to Tune the Activity of Tyrosine Phosphatases06:56

Author Spotlight: Developing Tools to Tune the Activity of Tyrosine Phosphatases

Published on: September 6, 2024

853
Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion07:30

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion

Published on: May 10, 2018

9.8K

Related Concept Videos

Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
4.7K
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
934
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.2K
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
871
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
1.3K
Protein Kinases and Phosphatases02:54

Protein Kinases and Phosphatases

Proteins undergo chemical modifications that trigger changes in the charge, structure, and conformation of the proteins. Phosphorylation, acetylation, glycosylation, nitrosylation, ubiquitination, lipidation, methylation, and proteolysis are various protein modifications that regulate protein activity. Such modifications are usually enzyme-driven.
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
15.5K